Table 2.
Patients’ status and treatments received before CP therapy.
| Characteristic | Total n = 27 |
EN group n = 15 |
LN group n = 12 |
P value |
|---|---|---|---|---|
| Interval between symptom onset and transfusion, median (IQR)—d | 45.0 (35.0–49.0) | 40.0 (26.0–47.0) | 45.5 (41.2–57.0) | 0.075 |
| Interval between symptom onset and last positive test before CP therapy, median (IQR)—d | 44.0 (30.0–47.0) | 39.0 (24.0–45.0) | 44.5 (38.2–54.7) | 0.126 |
| Body temperature, median (IQR)—°C | 36.9 (36.6–37.0) | 36.8 (36.5–37.2) | 36.9 (36.7–37.0) | 0.516 |
| Fever—no. (%) | 6 (22.2) | 4 (26.6) | 2 (16.6) | 0.662 |
| Oxygen therapy—no. (%) | ||||
| No oxygen treatment | 19 (70.3) | 10 (66.6) | 9 (75.0) | 0.696 |
| Nasal catheter oxygen therapy | 3 (11.1) | 3 (20) | 0 (0) | |
| Mechanical ventilation | 5 (18.5) | 2 (13.3) | 3 (25.0) | 1.000 |
| Extracorporeal membrane oxygenation | 1 (3.7) | 1 (6.6) | 0 (0) | |
| Fraction of inspiration O2 (n = 26), median (IQR)—% | 21.0 (21.0–33.0) | 21.0 (21.0–33.0) | 21.0 (21.0–35.2) | 0.809 |
| Respiratory rate > 24 times/min—no. (%) | 5 (18.5) | 3 (20) | 2 (16.6) | 1.000 |
| Peripheral oxygen saturation, median (IQR)—% | 98.0 (97.0–99.0) | 97.0 (97.0–99.0) | 97.0 (97.0–98.5) | 0.905 |
| Vasopressors—no. (%) | 4 (14.8) | 1 (6.6) | 3 (25.0) | 0.294 |
| Anti-virus therapy—no. (%) | ||||
| Ribavirin | 4 (14.8) | 2 (13.3) | 2 (16.6) | 1.000 |
| Lopinavir | 8 (29.6) | 3 (20.0) | 5 (41.6) | 0.398 |
| Favipiravir | 2 (7.4) | 2 (13.3) | 0 (0) | |
| Definite or suspected coinfection—no. (%) | 6 (22.2) | 3 (20.0) | 3 (25.0) | 0.433 |
| Broad-spectrum antibiotic therapy—no. (%) | 15 (55.5) | 8 (53.3) | 7 (58.3) | 1.000 |
| Corticoid therapy—no. (%) | 5 (18.5) | 3 (20) | 2 (16.6) | 1.000 |
| Immunoglobulin therapy—no. (%) | 6 (22.2) | 4 (26.6) | 2 (16.6) | 0.662 |